CA2293400A1 - Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine - Google Patents

Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine Download PDF

Info

Publication number
CA2293400A1
CA2293400A1 CA002293400A CA2293400A CA2293400A1 CA 2293400 A1 CA2293400 A1 CA 2293400A1 CA 002293400 A CA002293400 A CA 002293400A CA 2293400 A CA2293400 A CA 2293400A CA 2293400 A1 CA2293400 A1 CA 2293400A1
Authority
CA
Canada
Prior art keywords
group
heteroaryl
protein tyrosine
carboxy
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002293400A
Other languages
English (en)
Inventor
Gerald Mcmahon
Peng Cho Tang
John Y. Ramphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2293400A1 publication Critical patent/CA2293400A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La présente invention concerne de nouveaux composés hétéroaryle, des sels physiologiquement acceptables et des promédicaments de ceux-ci, destinés à moduler l'activité des enzymes protéine tyrosine qui sont associées à la transduction de signaux cellulaires, en particulier l'activité de la protéine tyrosine phosphatase. Lesdits composés sont donc destinés à être utilisés dans la prévention et le traitement de troubles associés à la transduction anormale de signaux cellulaires associée à des enzymes protéine tyrosine, telle que le cancer et le diabète.
CA002293400A 1997-06-13 1998-06-12 Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine Abandoned CA2293400A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4956097P 1997-06-13 1997-06-13
US60/049,560 1997-06-13
PCT/US1998/012333 WO1998056376A1 (fr) 1997-06-13 1998-06-12 Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Publications (1)

Publication Number Publication Date
CA2293400A1 true CA2293400A1 (fr) 1998-12-17

Family

ID=21960475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293400A Abandoned CA2293400A1 (fr) 1997-06-13 1998-06-12 Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Country Status (5)

Country Link
EP (1) EP1007042A4 (fr)
JP (1) JP2002512628A (fr)
AU (1) AU8071698A (fr)
CA (1) CA2293400A1 (fr)
WO (1) WO1998056376A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
JP2002507598A (ja) * 1998-03-26 2002-03-12 スージェン・インコーポレーテッド チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
RU2312860C2 (ru) * 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1438310B1 (fr) 2001-10-19 2006-12-20 TransTech Pharma Inc. Derives de beta-carboline en tant qu'inhibiteurs de ptp
ES2330927T3 (es) * 2001-11-28 2009-12-17 Ipsen Pharma Derivados de 5-sulfanil-4h-1,2,4-triazoles para tratar trastornos asociados a la somatostatina.
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
WO2005035551A2 (fr) 2003-10-08 2005-04-21 Incyte Corporation Inhibiteurs de proteines se liant a des molecules phosphorylees
TW200602337A (en) 2004-02-25 2006-01-16 Wyeth Corp Inhibitors of protein tyrosine phosphatase 1B
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (fr) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Composés hétéroarylbenzimidazole substitués
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
AU2018210196B2 (en) * 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3185865A1 (fr) 2017-07-14 2019-01-17 F. Hoffmann-La Roche Ag Composes cetoniques bicycliques et leurs procedes d'utilisation
WO2019051084A1 (fr) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Compositions d'inhibiteur de la shp2 et méthodes de traitement du cancer
KR20200070297A (ko) 2017-10-11 2020-06-17 에프. 호프만-라 로슈 아게 Rip1 키나아제 억제제로서 사용하기 위한 이환형 화합물
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
PE20211247A1 (es) * 2017-10-31 2021-07-13 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos
RU2020123241A (ru) 2017-12-15 2022-01-17 Революшн Медсинз, Инк. Полициклические соединения в качестве аллостерических ингибиторов shp2
US20190336609A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
AU2021342568A1 (en) 2020-09-21 2023-04-20 Landos Biopharma, Inc. Nlrx1 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds

Also Published As

Publication number Publication date
WO1998056376A1 (fr) 1998-12-17
AU8071698A (en) 1998-12-30
JP2002512628A (ja) 2002-04-23
EP1007042A4 (fr) 2001-07-04
EP1007042A1 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
CA2293400A1 (fr) Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
US6143765A (en) Pharmaceutical compositions and methods for modulating signal transduction
US6080772A (en) Thiazole compounds and methods of modulating signal transduction
EP1212296B9 (fr) Mimetiques phosphates et procedes de traitement utilisant des inhibiteurs de phosphatase
Bayindir et al. The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes
MXPA96006404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales
US5602171A (en) Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
US6656940B2 (en) Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US5780496A (en) Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
EP1805155B1 (fr) Composes et methodes visant a reguler l'activite de la thrombopoietine
Ottanà et al. Discovery of 4-[(5-arylidene-4-oxothiazolidin-3-yl) methyl] benzoic acid derivatives active as novel potent allosteric inhibitors of protein tyrosine phosphatase 1B: In silico studies and in vitro evaluation as insulinomimetic and anti-inflammatory agents
JP2013510824A (ja) セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
CA2342222A1 (fr) Derives de 2-indolinone a geometrie limitee utilises en tant que modulateurs de l'activite de la proteine kinase
US20070293484A1 (en) Thiophene Heteroaryl Amines
AU2003300447B2 (en) Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
Kumar et al. p-TSA. H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer
WO1996040113A2 (fr) Inhibiteurs de la phosphatase
Ghorab et al. Novel sulfonamide derivatives carrying a biologically active 3, 4-dimethoxyphenyl moiety as VEGFR-2 inhibitors
CA2860413C (fr) Utilisation therapeutique de derives d'imidazopyridine
JPH10175863A (ja) シグナル伝達をモジュレートするための医薬組成物および方法
KR20130108876A (ko) Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법
Al Neyadi et al. Novel Thiazolidinedione and Rhodanine Derivatives Regulate Glucose Metabolism, Improve Insulin Sensitivity, and Activate the Peroxisome Proliferator-Activated γ Receptor
JP2004536127A (ja) キナーゼ阻害剤及びその使用
WO2005113561A1 (fr) Cyclicsulfonate pyrrole indolinones en tant qu'inhibiteurs de kinase

Legal Events

Date Code Title Description
FZDE Dead